Zekerie Redzheb Editorial Consultant

Zekerie holds a master’s degree in Virology and tutors both general and molecular biology. He has a vested interest in pandemic viruses and pathogen-host interactions. He is particularly interested in HIV cure research and HIV treatment, as well as environmental and sociocultural influences on the wellbeing of people living with HIV.

LinkedIn

Viral load

Experts publish recommendations on managing low-level but detectable HIV

Cancer

Lymphoma and HIV

Cancer

Worse HIV control at diagnosis doesn't mean worse lymphoma outcomes

Sexually transmitted infections prevention

DoxyPEP halves overall syphilis cases, with possible indirect benefits for women

Ageing & HIV

People with undetectable HIV age cognitively at the same rate as those without HIV

Antibody-based treatment

Antibody from Tanzanian woman suppresses almost all tested HIV variants including resistant viruses in pre-clinical study

The search for a cure

Turning HIV’s power against itself may help target hidden virus – another step towards a cure

Viral load

Low-level but detectable HIV raises the risk of treatment failure, but not long-term harm

Telling people you have HIV

Despite U=U, concerns about sharing HIV status persist among older people

Sexually transmitted infections prevention

Two doses of HPV vaccine as effective as the recommended three-dose schedule for women with HIV

Neurological & cognitive problems

A class of HIV drugs might protect against Alzheimer’s

Changing treatment

Changing HIV treatment

Viral load

What are logs in viral load results?

HIV treatment

HIV lifecycle

The search for a cure

Varying dolutegravir distribution across the body may affect the drug’s ability to suppress the HIV reservoir

HIV treatment

Dolutegravir-based triple therapy effectively suppresses HIV-2 viral load in small study

Resistance

Dolutegravir resistance is rare, but some risk factors can up the odds

The search for a cure

Gene editing may not be the safest HIV cure strategy, early findings warn